VI. Endometriumkarzinom
7. PROGNOSE
– Tumorausbreitung/anatomisches Stadium (im Rahmen der Primäroperation gesicherte Tumorausbreitung inklusive LK-Befalls)
– molekulare Klassifizierung laut TCGA (Kandoth et al., 2013) (siehe Tab. 3).
– histologische Entität (nicht-endometrioide Karzinome: schon bei geringem myometranen Befall rasch Lymph- und Gefäßbahninvasion und früh Adnex- bzw. Fernmetastasen)
– Differenzierungsgrad
–Östrogenrezeptor-Status
– ethnischer Hintergrund (afrikanischer Hintergrund mit höherem Risiko für undifferenzierte und nicht-endometrioide Karzinome vs. Kaukasierinnen)
- • LVSI (Lymph-vascular Space Invasion): Vor allem der substanzielle Lymphgefäßbefall erhöht sowohl das Lokalrezidiv- als auch das Fernrezidiv-Risiko.
- • Vermehrt auch Hinweise auf Alter > 60 Jahreals negativer Prognosefaktor.
Zur NACHSORGE siehe Kapitel XII: „Nachsorge bei Frauen nach gynäkologischen Krebserkrankungen“ (Seite 174)
–Aslan D.L., Crapanzano J.P., Harshan M., Erroll M., Vakil B., Pirog E.C.: The Bethesda System 2001: recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol 2007; 107 (1): 86–93
–Baak J.P., Mutter G.L., Robbey Set al.: The molecular genetics and morphometry- based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005; 103: 2304–12
–Baek J.S., Lee W.H., Kang W.D., Kim S.M.: Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective? Obstet Gynecol Sci 2016; 59 (1): 24–31. doi: 10.5468/ogs.2016.59.1.24
–Beal H.N., Stone J., Beckmann M.J., McAsey M.E.: Endometrial cells identified in cervical cytology in women > or = 40 years of age: criteria for appropriate endometrial evaluation. Am J Obstet Gynecol 2007; 196 (6): 568.e1–5; discussion 568.e5–6
–Ben-Arie A., Goldchmit C., Laviv Y., Levy R., Caspi B., Huszar M., Dgani R., Hagay Z.: The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol 2004; 115 (2): 206–210
–Ben-Arie A., Tamir S., Dubnik S., Gemer O., Ben Sushan A., Dgani R., Peer G., Barnett-Griness O., Lavie O.: Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer 2008; 18 (4): 813–819
–Berek J.S. et al.: FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162 (2): 383: 394
–Bogani G., Murgia F., Ditto A., Raspagliesi F.: Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol 2019; 153: 676–683
–Concin N., Matias-Guiu X., Cibula D., Colombo N., Creutzberg C.L., Ledermann J., Mirza M.R., Vergote I., Abu-Rustum N.R., Bosse T., Chargari C., Espenel S., Fagotti A., Fotopoulou C., Gatius S., González-Martin A., Lax S., Levy B., Lorusso D., Macchia G., Marth C., Morice P., Oaknin A,, Raspollini M.R., Schwameis R, Sehouli J., Sturdza A., Taylor A., Westermann A., Wimberger P., Planchamp F., Nout R.A.: ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma – Update 2025. Lancet Oncol 2025; in Druck befindlich
–Courneya K.S., Karvinen K.H., Campbell K.L., Pearcey R.G., Dundas G., Capstick V. et al.: Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol 2005; 97: 422–430
–Dijkhuizen F.P., Mol B.W., Brölman H.A., Heintz A.P.: The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89: 1765–72
–Fader A.N., Roque D.M., Siegel E., Buza N., Hui P., Abdelghany O. et al.: Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol 2018; 36: 2044–2051
–Ferguson S.E. et al.: Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006; 101: 322–326
–Ferrari F. et al.: Early non-compliance to ERAS in gynecological open surgery for malignancies, and post-operative complications: a multicenter, prospective, observational, cohort study. Int J Gynecol Cancer 2025; doi: 10.1136/ijgc-2024-005648. Online ahead of print
–Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., Kline R., Burger R.A., Goodman A., Burks R.T.: Phase III trial of doxorubicinplus cisplatin with or without paclitaxel plus filgastrim in advancedendometrial carcinoma: a Gynecologic Oncology Group Study. J ClinOncol 2004; 22 (11): 2159–2166
–Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., VaccarelloL., Gallion H.: Phase III rancomized trial of doxorubicin plus cisplatin versus doxorubicin plus 24 h paclitaxel plus filgastrim in endometrial carcinoma: a Gynecologic Oncology Group Study. Ann Oncol 2004; 15 (8): 1173–1178
–Fotopoulou C., Kraetschell R., Dowdy S., Fujiwara K., Yaegashi N., Larusso D., Casado A., Mahner S., Herzog T.J., Kehoe S., Vergote I., Miller D.S., Marth C., Fujii S., Sehouli J.: Surgical and systemic management of endometrial cancer: an international survey. Arch Gynecol Obstet 2015; 291 (4): 897–905
–Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207 (4): 266.e1–12. doi: 10.1016/j.ajog.2012.08.011
–Gehrig P.A., Van Le L., Olatidoye B., Geradts J.: Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86 (10): 2083–2089
–Gull B., Carlsson S., Karlsson B., Ylöstalo P., Milsom I., Granberg S.: Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol 2000; 182 (3): 509–515
–Haltia U.-M., Bützow R., Leminen A., Loukovaara M.: FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype. J Gynecol Oncol 2014; 25 (1): 30–35
–Havrilesky L.J., Cragun L.M., Calingaert B., Alvarez Secord A., Valea F.A., Clarke-Pearson D.L, Berchuck A., Soper J.T.: The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 2007; 104 (2): 401–405
–Kandoth C., Schultz N., Cherniack A.D., Akbani R. et al.: Integrated genomic characterization of endometrial carcinoma. Cancer Genome Atlas Research Network. Nature 2013; 497: 67–73
–Khoury-Collado F., St. Clair C., Abu-Rustum N.R.: Sentinel Lymph Node Mapping in Endometrial Cancer: An Update. Oncologist 2016; 21: 461–466
–Kommoss F.K.F., Karnezis A.N., Kommoss F., Talhouk A. et al.: L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 2018; 119: 480–486
–Kommoss S. et al.: Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29 (5): 1180–1188
–Korczynski J., Jesionek-Kupnicka D., Gottwald L., Piekarski J.: Comparison of FIGO 1989 and 2009 Recommendations on Staging of Endometrial Carcinoma: Pathologic Analysis and Cervical Status in 123 Consecutive Cases. International Journal of Gynecological Pathology 2011; 30 (4): 328–334
–Kurman R.J., Kaminski P.F., Norris H.J.: The behavior of endometrial hyperplasia. A long-term study of „untreated“ hyperplasia in 170 patients. CA Cancer J Clin 1985; 56: 403–12
–Kwon J.S., Francis J.A., Qiu F. et al.: When is a pathology review indicate in endometrial cancer? Obstet Gynecol 2007; 110: 1224
–Lacey J.V. Jr., Sherman M.E., Rush B.B. et al.: Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28: 788–92
–Lambrou N.C., Gomez-Martin O., Mirhashemi R., Beach H., Salom E., Almeida- Parra Z., Penalver M.: Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004; 93 (3): 653–58
–Miller D., Filiaci V., Fleming G., Mannel R., Cohn D., Matsumoto T. et al.: Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 771
–Miller D.S., Filiaci V.L., Mannel R.S., Cohn D.E. et al.: Carboplatin and Paclitaxel for advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol 2020; 38 (33): 3841–3850
–Parslov M., Lifegaard Ø., Klintrop S., Pedersen B., Jønsson L., Eriksen P. S., Ottesen B.: Risk factors among young women with endometrial cancer: A Danish case-control study. Am J Obstet Gynecol 2000; 182: 23–29
–Pecorelli S.: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol and Obstet 2009; 105: 103–104
–Radolakis A. et al.: ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Int J Gynecol Cancer 2023; 33(2): 208–222
–Ronnett B.M., Kurman R.J.: Precursor Lesions of Endometrial Carcinoma. In: Blausteins Pathology of the female genital tract. Editor: Robert J.Kurman, Fifth Edition 2002, Springer Verlag, New York, Berlin, Heidelberg
–Silverman M.B., Roche P.C., Kho R.M., Keeney G.L., Li H., Podratz K.C.: Molecular and cytokinetic pretreatment risk in endometrial carcinoma. Gynecol Oncol 2000; 77 (1): 1–7
–Smith-Bindman R., Weiss R., Feldstein V.: How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24: 558
–Statistik Austria, Österreichisches Krebsregister (Stand: Stand 02.10.2015)
–Thipgen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S.: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004 1; 22 (19): 3902–3908
–Timmermans A., Opmeer B.C., Khan K.S. et al.: Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 160–67
–Trimble C.L., Kauderer J., Zaino R., Silverberg S., Lim P.C., Burke J.J.2nd, Alberts D., Curtin J.: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006 Feb; 106: 812–819
–Uccella S. et al.: A randomized controlled trial on the oncologic outcomes of use of the intrauterine manipulator in the treatment of apparent uterine-confined endometrial carcinoma: the MANEC Trial. Int J Gynecol Cancer 2024; 34 (12): 1971–1975
–Wright T.C. Jr., Massad S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D., for the 2006 American society for Colposcopy and Cervical Pathology – sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening test. Am J Obstet Gynecol 2007 Oct; 346–355
–Zeimet A.G., Reimer D., Huszar M., Winterhoff B., Puistola U., Abdel-Azim S., Müller-Holzner E., Ben-Arie A., van Kempen L.C., Petru E. et al.: L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013; 105: 1142-1150
